SEIMED | SPAIN

.Búsqueda de socios

Publique su oferta/demanda

 

Developer/Manufacturer of Oto Acoustic Emissions (OAE) measurement devices sought for technological collaboration (TOIL20170726001)


 ISRAEL

Technology collaboration OFFER
Created: 26/07/2017
Last updated: 02/08/2017
Fecha límite: 02/08/2018

Resumen

Developer/manufacturer of Oto Acoustic Emissions measurement devices is sought to integrate an exciting and innovative ICT solution enabling the very early diagnosis of Sensory Perception disorders, most noteworthy in Autism. This diagnostic device will enable very early detection (in newborns), allowing for application of behavioural modification interventions at a very early age that will result in remarkably better social integration. Licence, research or technical cooperations are possible.


Partnership(s) sought

  • License agreement Technical cooperation agreement Research cooperation agreement

Descripción completa

Currently, Autism is diagnosed through a process which is subjective, lengthy and can only be performed when behavioural markers are apparent, that is, not before a child is at least between one and a half to two years of age. Realizing that people with Autism in all its forms have sensory processing issues, the Israeli company monitors sensory processing performance by monitoring the ear’s acoustic output: Oto-Acoustic Emissions (OAE - the stochastic like, reflex audio signals generated in the inner ear’s cochlea by the outer hair cells). OAE is an important player in the sensory perception of all senses and as such is an indicator of their performance. This procedure is objective, short, non-invasive and can be performed even on newborns. The company aims to include this procedure in the standard battery of tests performed on every newborn, enabling the full benefit of early interventions on functionality, and also realizing the cost savings associated with this improved functionality.
A range of educational and behavioural support programs can help Autistic patients. The importance of applying interventions as early as possible is clearly recognized by the success rate in ingraining social skills – which exceeds 90% if interventions are applied before the age of two as opposed to only 11% when applied after the age of five. The need for an objective diagnosis of Autism that can be applied at a very early developmental stage is well established. The immediate benefit is the ability to apply behaviour modification interventions early on for significantly improved results, allowing for a much better chance of social integration of the patient. In addition, an objective and fast diagnosis is an invaluable tool for research leading to better understanding of this disability which may result in a cure.
The company is looking to partner with a major developer/manufacturer of OAE devices in order to add this technology to their equipment. This will ensure the highest accuracy of the diagnosis, as well as quick market penetration.


Socio buscado:

- Specific area of activity of the partner: The company is looking to partner with a major developer/manufacturer of OAE devices in order to add this technology to their equipment. This will ensure the highest accuracy of the diagnosis, as well as quick market penetration. The company is open to various options for cooperation, depending upon the partnering company, inter alia a license agreement, or a research cooperation or technical cooperation agreement.


Advantages & innovations:

An Israeli company has developed an innovative technology that enables the measurement of sensory perception performance as a marker of Autism. The measurement procedure is short, non-invasive and requires no cooperation on the part of the subject, and therefore measurements can be taken as early as days after birth.
The technology provides an easily accessible, objective diagnosis of sensory processing disorders that is not dependent on professional assessors. It is applicable as a screening tool for newborns as no cooperation is required from the tested subject, enabling very early detection and intervention. There is no other screening test today for Autism that can be performed on newborns.
The company aims to include this procedure in the standard battery of tests performed on every newborn, enabling the full benefit of early interventions on the Autistic child’s functionality.


Development Stage:

Field tested/evaluated


IPR:

Patent(s) applied for but not yet granted - Two patents pending

Clasificado como: Medicine and Health


Seleccione una de las siguientes opciones para interesarse por esta oportunidad:

Para enviarnos una expresión de interés acerca de este perfil por favor conteste a la siguiente pregunta

Tiene su empresa sede en la Comunidad Valenciana o la Región de Murcia?

   NO